Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACLY | P53396 | 1/20 | 0.53 |
| ▸ | CCKAR | P32238 | 13/20 | 0.53 |
| ▸ | CCKBR | P32239 | 13/20 | 0.53 |
| ▸ | ITGB1 | P05556 | 1/20 | 0.47 |
| ▸ | ITGA4 | P13612 | 1/20 | 0.47 |
| ▸ | CA1 | P00915 | 1/20 | 0.47 |
| ▸ | CA2 | P00918 | 1/20 | 0.47 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.46 |
| ▸ | PDK1 | Q15118 | 1/20 | 0.45 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.45 |
| ▸ | PDK3 | Q15120 | 1/20 | 0.45 |
| ▸ | PDK4 | Q16654 | 1/20 | 0.45 |
| ▸ | HTT | P42858 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5926535 | 0.92 | ACLY (0.50) | ACLYCCKARCCKBRMCL1 | |
| SCHEMBL8339983 | 0.91 | CCKAR (0.54) | CCKARCCKBRITGB1ITGA4CA1 | |
| SCHEMBL5926353 | 0.91 | CCKAR (0.54) | CCKARCCKBRITGB1ITGA4CA1 | |
| SCHEMBL8337571 | 0.91 | ACLY (0.49) | ACLYCCKARCCKBRITGB1ITGA4 | |
| SCHEMBL6097972 | 0.90 | ACLY (0.53) | ACLYCCKARCCKBRITGB1ITGA4 | |
| SCHEMBL5927106 | 0.87 | CCKAR (0.53) | ACLYCCKARCCKBRITGB1ITGA4 | |
| SCHEMBL5926476 | 0.85 | ACLY (0.52) | ACLYCCKARCCKBRMCL1 | |
| SCHEMBL8337865 | 0.84 | CCKAR (0.51) | CCKARCCKBRITGB1ITGA4 | |
| SCHEMBL8340240 | 0.83 | KCNA5 (0.60) | CCKARCCKBRITGB1ITGA4 | |
| SCHEMBL5926755 | 0.83 | KCNA5 (0.60) | CCKARCCKBRITGB1ITGA4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060276518-A1 | Aryl and heteroaryl compounds and methods to modulate coagulation | TRANSTECH PHARMA, INC. | 2006-12-07 | — | — | US | disclosed |
| US-7122580-B2 | Aryl and heteroaryl compounds and methods to modulate coagulation | TRANSTECH PHARMA, INC. (US) | 2006-10-17 | — | — | US | disclosed |
| WO-2004014844-A2 | ARYL AND HETEROARYL COMPOUNDS AND METHODS TO MODULATE COAGULATION | TRANSTECH PHARMA, INC. (US) | 2004-02-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060276518-A1 | Aryl and heteroaryl compounds and methods to modulate coagulation | TFPI, F9, F2 | ACLY 3952/4885CCKAR 514/4885CCKBR 692/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.